Antioestrogens and breast cancer

Santhanam, S. & O'Byrne, Kenneth J. (2001) Antioestrogens and breast cancer. Journal of the British Menopause Society, 7(1), pp. 21-26.

View at publisher


Antioestrogens are among the most widely used agents in the treatment of breast cancer. There has been a recent surge of interest in these compounds because of their potential breast cancer chemopreventive properties. The newer generation of antioestrogens, with increased selectivity and better toxicity profiles, have the potential to increase the effectiveness of hormonal treatment of breast cancer. The selective oestrogen receptor modulators (SERMs) hold the promise of revolutionising the care of healthy postmenopausal women with their beneficial effects on bone and lipids in addition to the chemoprevention of breast cancer.

Impact and interest:

0 citations in Scopus
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 65381
Item Type: Journal Article
Refereed: No
Additional URLs:
Keywords: Antioestrogens, Breast cancer, Postmenopausal women, Raloxifene, Selective oestrogen receptor modulators, Tamoxifen, 4 [4 methyl 2 [4 [2 (1 piperidinyl)ethoxy]phenyl] 7 pivaloyloxy 2h 1 benzopyran 3 ylphenyl] pivalate, acolbifene, antiestrogen, aromatase inhibitor, arzoxifene, centchroman, cholesterol, diethylstilbestrol, droloxifene, estradiol derivative, estrogen, estrogen receptor, estrogen receptor alpha, estrogen receptor beta, fulvestrant, high density lipoprotein cholesterol, idoxifene, lasofoxifene, lipid, lipoprotein A, low density lipoprotein cholesterol, ly 336156, miproxifene phosphate, n butyl 11 (3, 17beta dihydroxyestra 1, 3, 5(10) trien 7alpha yl) n methylundecanamide, progesterone receptor, selective estrogen receptor modulator, toremifene, triacylglycerol, unclassified drug, unindexed drug, advanced cancer, binding affinity, bone remodeling, cancer inhibition, cancer prevention, cancer radiotherapy, cancer surgery, cardiovascular effect, clinical trial, cross resistance, drug classification, drug efficacy, drug inhibition, drug receptor binding, drug selectivity, drug tolerability, drug use, endometrium cancer, fatigue, gastrointestinal symptom, genetic transcription, hormonal therapy, hot flush, human, lipid metabolism, menopausal syndrome, nonhuman, postmenopause, review, thromboembolism
DOI: 10.1258/136218001100321083
ISSN: 1362-1807
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2001 British Menopause Society
Deposited On: 13 Dec 2013 00:53
Last Modified: 13 Dec 2013 00:53

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page